Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Cost of Revenue (2016 - 2025)

Immucell (ICCC) has disclosed Cost of Revenue for 16 consecutive years, with -$5.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 795.24% year-over-year to -$5.9 million, compared with a TTM value of $7.4 million through Sep 2025, down 26.44%, and an annual FY2024 reading of $18.6 million, up 36.39% over the prior year.
  • Cost of Revenue was -$5.9 million for Q3 2025 at Immucell, down from $7.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $9.0 million in Q4 2021 and bottomed at -$5.9 million in Q3 2025.
  • Average Cost of Revenue over 5 years is $2.2 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Cost of Revenue soared 468.24% in 2023, then crashed 795.24% in 2025.
  • Year by year, Cost of Revenue stood at $9.0 million in 2021, then crashed by 88.94% to $992556.0 in 2022, then surged by 316.06% to $4.1 million in 2023, then grew by 19.13% to $4.9 million in 2024, then plummeted by 219.28% to -$5.9 million in 2025.
  • Business Quant data shows Cost of Revenue for ICCC at -$5.9 million in Q3 2025, $7.5 million in Q2 2025, and $856658.0 in Q1 2025.